drugset / Trial / NCT05149339

Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in Leukemia

NCT05149339

Phase 1/2 Completed 38 enrolled Zagazig University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Disintegrin-like And Metalloprotease with Thrombospondin type 1 motif 13 (ADAMTS13) deficiency was incriminated in poor prognosis, high probability of serious complications and mortality in acute myeloid leukemia (AML) patients. Interleukin 6 (IL-6) produced from AML blasts decreases Cluster of differentiation 34 positive(CD34+) cells differentiation, and inhibits the ADAMTS13 actions. Vitamin D "as an Immune-modulator" inhibits the pro-inflammatory cytokines including IL-6. So, supplementation of vitamin D might help down regulation of interleukin-6 production. Aim of the study To evaluate the potential relation between Vitamin D status, ADAMTS13 and IL-6 in AML patients. Objectives 1. Assess Vitamin D level in AML patients 2. Assess ADAMTS13 and IL-6 in AML patients 3. Correlate between Vitamin D level and both of ADAMTS13 and IL-6

Timeline

Start
2019-03-01
Primary completion
2020-02-01
Completion
2021-03-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 2800 iu Oral